来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 10-23 16:08:09

5.765

+0.055

+0.96%

最高5.800	最低5.295	成交量166.95万
今开5.500	昨收5.710	日振幅8.84%
总市值26.06亿	流通市值26.06亿	总股本4.52亿
成交额925.04万	换手率0.37%	流通股本4.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":5.765,"timestamp":1792742889004,"preClose":5.71,"halted":0,"volume":1669500,"delay":0,"changeRate":0.009632224168126044,"floatShares":451999999,"shares":451999999,"eps":-0.59,"marketStatus":"休市中","change":0.055,"latestTime":"10-23 16:08:09","open":5.5,"high":5.8,"low":5.295,"amount":9250446,"amplitude":0.088441,"askPrice":5.795,"askSize":500,"bidPrice":5.765,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.26,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":5.71,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":1.489561027996741,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"2675392189","title":"港股异动 | 来凯医药-B(02105)涨超5% 已完成LAE102为期24周单药治疗研究低剂量组别治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675392189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675392189?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:18","pubTimestamp":1791947911,"startTime":"0","endTime":"0","summary":"消息面上，10月13日，来凯医药-B发布公告，本集团已完成LAE102为期24周单药治疗研究低剂量组别的治疗。该数据与LAE102此前的单剂量递增及多剂量递增研究结果一致，显示出身体成分的积极变化。为期24周的治疗耐受性良好，未报告任何严重不良事件，亦无腹泻、肌肉痉挛或痤疮等报告，与先前披露的SAD及MAD研究结果一致。LAE102高浓度制剂近期已就绪，本集团已完成高剂量组别的受试者入组，以进一步评估LAE102在24周治疗期内高剂量水平下的疗效及安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","BK1161","BK4585","BK4588","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675132392","title":"港股异动 | 来凯医药-B(02105.HK)涨超5% 已完成LAE102为期24周单药治疗研究低剂量组别治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675132392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675132392?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:18","pubTimestamp":1791947911,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191820006","title":"来凯医药-B（02105）完成LAE102低剂量24周单药研究并启动高剂量组入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1191820006","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191820006?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:15","pubTimestamp":1791850559,"startTime":"0","endTime":"0","summary":"2026年10月13日，来凯医药-B发布自愿公告称，公司已完成LAE102为期24周的低剂量单药治疗研究。结果显示，该组别在体重管理方面取得“令人鼓舞”的减重效果，并观察到肌肉增加与脂肪减少的积极体成分变化。公司表示，LAE102高浓度制剂已准备就绪，已完成高剂量组受试者入组，拟在同样的24周治疗期内进一步评估其疗效与安全性。公司提示，LAE102最终可能无法实现成功开发及商业化，提醒股东及潜在投资者交易公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675850923","title":"来凯医药-B(02105.HK)已完成LAE102为期24周单药治疗研究低剂量组别的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675850923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675850923?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:13","pubTimestamp":1791850403,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153198524","title":"来凯医药-B更新2026年9月股份变动月报 新增发行2,730,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153198524","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153198524?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:36","pubTimestamp":1791362198,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年10月7日公布了截至2026年9月30日的证券变动月报表。报告期内，公司法定/注册股本总额维持50,000美元不变，注册资本中普通股数量依然为5,000,000,000股，面值0.00001美元/股。在已发行股份方面，截至2026年8月末，来凯医药-B已发行普通股449,331,350股，报告期内新增发行2,730,000股，期末已发行股份总数上升至452,061,350股。本月通过2024年6月14日采纳的2024年股份奖励计划增发2,730,000股普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225842","title":"港股异动 | 来凯医药-B(02105)早盘涨超21% LAE118的I期临床研究近期完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225842","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225842?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:30","pubTimestamp":1790739024,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B早盘涨超21%。截至发稿，涨18.33%，报7.585港元，成交额3283.41万港元。消息面上，来凯医药近日宣布，其自主研发的LAE118针对晚期实体瘤的I期临床研究受试者招募工作正在中国展开，首例入组已完成。此次临床研究主要评估LAE118单药及联合用药的安全性、耐受性、药代动力学和初步疗效，据悉，LAE118已获得中美两国新药临床试验申请批准，进入I期临床研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","02105","BK4585","VXUS","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183625312","title":"来凯医药-B2026年中期营收1.50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183625312","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183625312?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:58","pubTimestamp":1789743481,"startTime":"0","endTime":"0","summary":"来凯医药-B在2026年上半年实现营收1.50亿元。上年同期尚未体现相关收入，本期主要得益于外部授权交易及研发服务。公告显示，本期毛利达1.29亿元，毛利率约为86.1%。研发费用为0.97亿元，相较上年同期的1.05亿元下降了7.8%，主要系部分前期处于IND支持性阶段的候选药物于期内获得批准并已转入临床阶段，发现研究开支相应降低。管理费用为0.59亿元，相比上年同期的0.42亿元增长了38.5%，主要因以股份为基础的付款支出增加等因素所致。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B2026年中期营收1.50亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665202703","title":"来凯医药-B(02105)合共发行27.3万股以满足根据2024年股份奖励计划授予的RSU的归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2665202703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665202703?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年9月8日，该公司合共发行27.3万股普通股以满足根据2024年股份奖励计划授予的RSU的归属。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155209452","title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1155209452","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155209452?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:16","pubTimestamp":1788869764,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）于2026年9月8日公告，因根据2024年股份奖励计划向公司董事及其他参与人授予的限制性股票单位（RSU）归属，公司于当日分别发行1,125,000股和1,605,000股普通股，合计发行2,730,000股。\n本次发行股份占公告前公司已发行股本449,331,350股的约0.2504%及0.3572%，发行价格均为每股0港元。发行完成后，公司已发行股本增至452,061,350股，库藏股仍为0股。\n公司董事会已对本次股份发行进行正式授权，并确认本次发行依据相关上市规则及适用法律规定进行，相关董事会决议及手续已履行。公告由公司秘书柯晨煜签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149410627","title":"来凯医药-B更新8月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149410627","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149410627?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:12","pubTimestamp":1788513125,"startTime":"0","endTime":"0","summary":"来凯医药-B于2026年9月4日发布截至2026年8月31日的股份变动月报表。公告显示，公司当月注册股本及已发行股份均未发生变化，股本结构保持稳定。报告期末，公司已发行股份总数为449,331,350股，较上月底无任何增减调整。公告称，截至2026年8月末，公司就所发行的股份，已充分满足香港联交所主板上市规则所要求的公众持股量规定，并确认所有新增或变动均符合相关法规与上市要求，且获得董事会正式授权。公告由公司秘书柯晨煜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664229418","title":"港股异动 | 来凯医药-B(02105.HK)尾盘涨超7% LAE118 I期临床完成首例受试者入组 许可协议最高5.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664229418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664229418?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:34","pubTimestamp":1788420853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882311","title":"港股异动 | 来凯医药-B(02105)早盘涨超9% LAE118的I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882311?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:46","pubTimestamp":1788227194,"startTime":"0","endTime":"0","summary":"消息面上，9月1日，来凯医药-B发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额外对价的情况下，获得Vasque Bio已发行普通股最高达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合资格战略合作或收购交易，集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","02105","BK4588","VXUS","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889447","title":"来凯医药-B(02105)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889447","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889447?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额 外 对 价 的 情 况 下 ， 获 得 Vasque Bio 已 发 行 普 通 股 最 高 达 高 双 位 数 百 分 比 的 股权，或替代该等普通股的现金付款。Vasque Bio主要专注于罕见疾病治疗药物的开发，集团则专注于在许可区域以外开 发LAE118 的肿瘤 疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889441","title":"来凯医药-B(02105.HK)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889441?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197062258","title":"来凯医药-B(02105)LAE118在华启动I期临床并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1197062258","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197062258?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:15","pubTimestamp":1788221745,"startTime":"0","endTime":"0","summary":"来凯医药-B9月1日发布自愿公告称，公司自研PI3Kα泛突变选择性抑制剂LAE118已在中国启动治疗晚期实体瘤的I期临床研究，并完成首例受试者入组。LAE118目前已获得美国食品药物管理局及中国国家药品监督管理局药品审评中心的新药临床试验批准。公告披露，2026年6月，公司与Vasque Bio, Inc.签署独家许可协议。来凯医药-B提醒投资者，LAE118最终未必能够成功开发及商业化，投资者在买卖公司证券时需审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765641","title":"来凯医药-B发布中期业绩 其他收入2596.2万元同比增加30.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765641","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765641?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:47","pubTimestamp":1787705220,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端来凯医药-B（02105）发布截至2026年6月30日止6个月的中期业绩，该集团取得取得其他收入2596.2万元（人民币，下同），同比增加30.41%；研发费用9700万元，同比减少7.79%；期内亏损254.9万元，同比减少98.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-26/doc-inipqxhc6330788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186487767","title":"来凯医药-B（02105）公布2026年中期业绩：收入1.50亿元，期内亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1186487767","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186487767?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:53","pubTimestamp":1787669581,"startTime":"0","endTime":"0","summary":"2026年8月25日，来凯医药-B发布截至2026年6月30日止六个月未经审计的中期业绩。期内，公司实现收入人民币150,277,000元，全部来自LAE118及LAE002对外授权交易。同期毛利为人民币129,415,000元；研发费用为人民币97,000,000元，同比减少7.8%。行政开支为人民币58,627,000元，同比增加38.5%。期内亏损大幅缩窄至人民币2,549,000元，公司将主要归因于对外授权收益的确认。截至2026年6月30日，公司持有现金及银行结余人民币941,820,000元，原到期日超过三个月的定期存款人民币180,660,000元，两项合计人民币1,122,480,000元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105172","title":"来凯医药-B(02105.HK)：预计中期收入1.45亿元至1.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105172","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660105172?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:37","pubTimestamp":1786927022,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨来凯医药-B(02105.HK)发布公告，截至2026年6月30日止六个月(“报告期间”)，集团预期录得：(i)报告期间收入约为人民币1.45亿元至人民币1.55亿元，去年同期截至2025年6月30日止六个月(“相应期间”)则为零；及(ii)报告期间综合净亏损不多于人民币500万元，去年相应期间综合净亏损约为人民币1.3亿元，即亏损按年大幅减少约96%。\r\n\r\n　　报告期间收入预期增加及综合净亏损大幅收窄，主要归因于与Vasque Bio, Inc.就LAE118及与齐鲁制药有限公司就LAE002(afuresertib)的独家许可协议确认的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32336435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118228633","title":"来凯医药-B发布正面盈利预告：上半年收入最高预计1.55亿元，净亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1118228633","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118228633?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:10","pubTimestamp":1786925441,"startTime":"0","endTime":"0","summary":"8月17日，来凯医药-B公告称，根据截至2026年6月30日止六个月的初步未经审计综合管理账目，公司预计：。公司预计将在2026年8月25日公布正式中期业绩。公司提醒股东及潜在投资者，以上数据仅供参考，买卖公司证券时务请审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659814091","title":"来凯医药-B(02105)：LAE002获CDE受理，AKT抑制剂国产重磅将至","url":"https://stock-news.laohu8.com/highlight/detail?id=2659814091","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659814091?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:45","pubTimestamp":1786581907,"startTime":"0","endTime":"0","summary":"阿斯利康开出2026Q2财报，肿瘤学资产AKT抑制剂Truqap俨然成为其中一颗亮眼明星。8月11日，来凯医药-B/齐鲁制药LAE002的NDA已获得CDE受理，预计将在2027年获批并商业化落地。3级不良事件发生率更低，是LAE002作为BIC的一项重要特征。LAE002负责阻断AKT通路这一关键耐药机制，二者联用形成“雄激素合成抑制+通路阻断”的双重打击。CAPItello-281的成功不能线性推出LAE002前列腺癌成功的充分条件，但AKT抑制剂能在前列腺癌兑现价值，已是板上钉钉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02105","LU1223082519.USD","XME","BK1161","GDXJ","SIL","LU1223082196.USD","SGDM","CDE","LU1223083913.SGD","BK4017"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.1265},{"period":"1month","weight":-0.1999},{"period":"3month","weight":-0.1103},{"period":"6month","weight":-0.6314},{"period":"1year","weight":-0.5582},{"period":"ytd","weight":-0.5752}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.072516},{"month":8,"riseRate":0.75,"avgChangeRate":0.06659},{"month":9,"riseRate":0.75,"avgChangeRate":0.102989},{"month":10,"riseRate":0.5,"avgChangeRate":0.005327},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}